Investors & Media
Company Overview
View All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.

Featured Release
LyGenesis Adds Inborn Errors of Metabolism, Orphan Pediatric Indications with Large Unmet Needs, to its Drug Development Pipeline
Novel approach first aims to treat pediatric patients with Maple Syrup Urine Disease
Read More